{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:57:49Z","timestamp":1787237869341,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Syqe Medical Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although current treatment guidelines recommend against cannabinoids for Post-Traumatic Stress Disorder (PTSD), their use has increased in clinical settings despite fragmented evidence. This review critically examines the efficacy, effectiveness, and safety of cannabinoid-based interventions for PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a scoping review following PRISMA-ScR guidelines. Five databases were searched up to December 22, 2024. Eligible studies included randomized controlled trials (RCTs) and observational studies, investigating cannabinoids in PTSD-diagnosed populations. Screening, extraction, and quality appraisal independently performed. Quality assessed using validated tools. Main outcomes included PTSD symptom severity and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1,474 screened titles, 26 studies included: 7 RCTs, 9 prospective, 9 retrospective observational studies, and one unpublished RCT, totaling 3,598 patients. Among the seven RCTs, only one demonstrated a statistically significant reduction in PTSD-related nightmares (nabilone vs. placebo). Two RCTs using inhaled or oral cannabis did not show superiority over placebo. Two additional RCTs evaluating oral THC during fear extinction tasks identified changes in neurobiological activation (e.g., increased ventromedial prefrontal cortex activity or reduced fear renewal) without clinical symptom improvement. The remaining two RCTs involving acute oral CBD administration showed minimal benefit, limited to transient mood or cognitive modulation during trauma recall. Overall, only one of the seven RCTs showed clear clinical efficacy over placebo; the rest showed no significant group differences. Observational studies frequently reported symptom improvements, particularly in nightmares, hyperarousal, sleep, and quality of life; however, these findings are limited by high risk of bias, reliance on self-reported outcomes, and lack of control groups, reducing confidence in causal interpretations. AEs were generally mild (e.g., dry mouth, dizziness). Risk of bias was high in most observational studies and moderate in RCTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current evidence from high-quality RCTs remains insufficient to support clinical use of cannabinoids in treating PTSD. The therapeutic role of cannabinoids in PTSD should be further evaluated through rigorous RCTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The review design was developed 'a priori' to data collection initiation but was not registered in PROSPERO prior to initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-026-00451-7","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:05:43Z","timestamp":1780016743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review"],"prefix":"10.1186","volume":"8","author":[{"given":"Joshua","family":"Aviram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rostislav","family":"Belobrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamit","family":"Grinapol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Fruchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"451_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","volume":"32","author":"M Aragona","year":"2009","unstructured":"Aragona M, Onesti E, Tomassini \u00deV, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in Multiple Sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"451_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13229-021-00420-2","volume":"12","author":"A Aran","year":"2021","unstructured":"Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid treatment for autism: a proof of concept randomized trial. Mol Autism. 2021;12(6):1\u201311. https:\/\/doi.org\/10.1186\/s13229-021-00420-2.","journal-title":"Mol Autism"},{"key":"451_CR3","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019;236:2713\u201324.","journal-title":"Psychopharmacology"},{"issue":"10","key":"451_CR4","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/070674370204701004","volume":"47","author":"GJG Asmundson","year":"2002","unstructured":"Asmundson GJG, Coons MJ, Taylor S, Katz J. PTSD and the experience of pain: Research and clinical implications of shared vulnerability and mutual maintenance models. Can J Psychiatry. 2002;47(10):930\u20137.","journal-title":"Can J Psychiatry"},{"issue":"6","key":"451_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Z Atakan","year":"2012","unstructured":"Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241\u201354.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"90","key":"451_CR6","first-page":"1","volume":"7","author":"J Aviram","year":"2025","unstructured":"Aviram J. Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025. J Cannabis Res. 2025;7(90):1\u201318.","journal-title":"J Cannabis Res"},{"issue":"5","key":"451_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","volume":"163","author":"J Aviram","year":"2021","unstructured":"Aviram J, Lewitus G, Vysotski Y, Berman P, Shapira A, Procaccia S, et al. Sex differences in medical Cannabis related adverse effects. Pain. 2021;163(5):975\u201383.","journal-title":"Pain"},{"issue":"105651","key":"451_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2021.105651","volume":"169","author":"J Aviram","year":"2021","unstructured":"Aviram J, Lewitus GM, Pud D, Procaccia S, Berman P, Yellin B, et al. Specific phytocannabinoid compositions are associated with analgesic response and adverse effects in chronic pain patients treated with medical cannabis. Pharmacol Res. 2021;169(105651):1\u201310. https:\/\/doi.org\/10.1016\/j.phrs.2021.105651.","journal-title":"Pharmacol Res"},{"issue":"11","key":"451_CR9","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.addbeh.2013.06.012","volume":"38","author":"KA Babson","year":"2013","unstructured":"Babson KA, Boden MT, Bonn-Miller MO. The impact of perceived sleep quality and sleep efficiency\/duration on cannabis use during a self-guided quit attempt. Addict Behav. 2013;38(11):2707\u201313. https:\/\/doi.org\/10.1016\/j.addbeh.2013.06.012.","journal-title":"Addict Behav"},{"issue":"4","key":"451_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jsat.2012.08.224","volume":"44","author":"KA Babson","year":"2013","unstructured":"Babson KA, Boden MT, Harris AH, Stickle TR, Bonn-Miller MO. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat. 2013;44(4):438\u201343. https:\/\/doi.org\/10.1016\/j.jsat.2012.08.224.","journal-title":"J Subst Abuse Treat"},{"key":"451_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-015-0032-7","volume":"10","author":"KA Belendiuk","year":"2015","unstructured":"Belendiuk KA, Baldini LL, Bonn-miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state- approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:1\u201310.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"451_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-32651-4","volume":"8","author":"P Berman","year":"2018","unstructured":"Berman P, Futoran K, Lewitus GM, Mukha D, Benami M, Shlomi T, et al. A new ESI-LC\/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):1\u201315.","journal-title":"Sci Rep"},{"key":"451_CR13","doi-asserted-by":"publisher","unstructured":"Bisson JI, Roberts NP, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;(12):1\u2013122. https:\/\/doi.org\/10.1002\/14651858.CD003388.pub4.","DOI":"10.1002\/14651858.CD003388.pub4"},{"issue":"12","key":"451_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"451_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1521-0391.2012.12018.x","volume":"22","author":"MT Boden","year":"2013","unstructured":"Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22(3):277\u201384.","journal-title":"Am J Addict"},{"issue":"7","key":"451_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M22-0217","volume":"175","author":"KF Boehnke","year":"2022","unstructured":"Boehnke KF, Dean O, Haffajee RL, Hosanagar A. Trends in registration for medical cannabis and reasons for use from 2016 to 2020. Ann Intern Med. 2022;175(7):1\u20138.","journal-title":"Ann Intern Med"},{"issue":"5","key":"451_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","volume":"239","author":"LM Bolsoni","year":"2022","unstructured":"Bolsoni LM, Crippa JAS, Hallak JEC, Guimar\u00e3es FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology. 2022;239(5):1499\u2013507. https:\/\/doi.org\/10.1007\/s00213-021-06043-y.","journal-title":"Psychopharmacology"},{"issue":"3","key":"451_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","volume":"44","author":"LM Bolsoni","year":"2022","unstructured":"Bolsoni LM, Crippa JAS, Hallak JEC, Guimaraes FS, Zuardi AW. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Braz J Psychiatry. 2022;44(3):298\u2013307.","journal-title":"Braz J Psychiatry"},{"issue":"4","key":"451_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/jts.20243","volume":"20","author":"MO Bonn-miller","year":"2007","unstructured":"Bonn-miller MO, Vujanovic AA, Feldner MT, Berenstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20(4):577\u201386.","journal-title":"J Trauma Stress"},{"issue":"2","key":"451_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/a0026621","volume":"5","author":"MO Bonn-miller","year":"2013","unstructured":"Bonn-miller MO, Boden MT, Drescher KD. Prospective investigation of the impact of Cannabis use disorders on Posttraumatic Stress Disorder symptoms among veterans in residential treatment. Psychol Trauma. 2013;5(2):193\u2013200.","journal-title":"Psychol Trauma"},{"issue":"2","key":"451_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/can.2020.0056","volume":"7","author":"MO Bonn-miller","year":"2022","unstructured":"Bonn-miller MO, Brunstetter M, Simonian A, Loflin MJ, Vandrey R, Babson KA, et al. The long-term, prospective, therapeutic impact of cannabis on Post-Traumatic Stress Disorder. Cannabis Cannabinoid Res. 2022;7(2):214\u201323.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3 March","key":"451_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0246990","volume":"16","author":"MO Bonn-Miller","year":"2021","unstructured":"Bonn-Miller MO, Sisley S, Riggs P, Yazar-Klosinski B, Wang JB, Loflin MJE, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One. 2021;16(3 March):1\u201326. https:\/\/doi.org\/10.1371\/journal.pone.0246990.","journal-title":"PLoS One"},{"issue":"5","key":"451_CR23","first-page":"583","volume":"247","author":"DJ Bremmer","year":"1982","unstructured":"Bremmer DJ, Southwick SM, Darnell A, Charney DS. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. JAMA. 1982;247(5):583.","journal-title":"JAMA"},{"key":"451_CR24","unstructured":"CADTH. Medical Cannabis \u2013 Research Gaps. 2019."},{"issue":"5","key":"451_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","volume":"34","author":"C Cameron","year":"2014","unstructured":"Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559\u201364.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"451_CR26","first-page":"385","volume":"10","author":"S Chan","year":"2017","unstructured":"Chan S, Blake A, Wolt A, Wan BA, Zaki P, Zhang L, et al. Medical cannabis use for patients with post-traumatic stress disorder (PTSD). J Pain Manag. 2017;10(4):385\u201396.","journal-title":"J Pain Manag"},{"key":"451_CR27","unstructured":"Straud,Casey. ClinicalTrials.com. Enhancing Prolonged Exposure with Cannabidiol to Treat Posttraumatic Stress Disorder. NCT05132699. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05132699."},{"issue":"2","key":"451_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.20882\/adicciones.858","volume":"30","author":"J Colom","year":"2018","unstructured":"Colom J, Gual A. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones. 2018;30(2):140\u201351.","journal-title":"Adicciones"},{"issue":"3","key":"451_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1037\/a0023076","volume":"25","author":"JR Cougle","year":"2011","unstructured":"Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. 2011;25(3):554\u20138.","journal-title":"Psychol Addict Behav"},{"key":"451_CR30","unstructured":"Cowling T, MacDougall D. Nabilone for the treatment of post-traumatic stress disorder: a review of clinical effectiveness and guidelines. CADTH Rapid Response Report: Summary with Critical Appraisal. Ottawa, Canada; 2019. Available from: https:\/\/europepmc.org\/article\/nbk\/nbk546995?report=printable&client=bot&client=bot&client=bot&client=bot#free-full-text."},{"key":"451_CR31","unstructured":"DEA. Drug Enforcement Agency. The Controlled Substances Act. 2018. Accessed November 20, 2024. 2018. Available from: https:\/\/www.dea.gov\/drug-information\/csa."},{"issue":"4","key":"451_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/acm.2018.0437","volume":"25","author":"L Elms","year":"2019","unstructured":"Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25(4):392\u20137.","journal-title":"J Altern Complement Med"},{"issue":"7","key":"451_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","volume":"79","author":"MA ElSohly","year":"2016","unstructured":"ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613\u20139. https:\/\/doi.org\/10.1016\/j.biopsych.2016.01.004.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"451_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","volume":"48","author":"A Englund","year":"2022","unstructured":"Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology. 2022;48(6):869\u201376.","journal-title":"Neuropsychopharmacology"},{"key":"451_CR35","unstructured":"EUDA. European Union Drugs Agency: Cannabis policy: status and recent developments. 2023. Available from: https:\/\/www.euda.europa.eu\/publications\/topic-overviews\/cannabis-policy\/html_en. Cited 2026 Jan 28."},{"issue":"2","key":"451_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1515\/jbcpp-2020-0279","volume":"33","author":"ML Forsythe","year":"2022","unstructured":"Forsythe ML, Boileau AJ. Use of cannabinoids for the treatment of patients with Post-traumatic stress disorder. J Basic Clin Physiol Pharmacol. 2022;33(2):121\u201332.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"1","key":"451_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","volume":"15","author":"GA Fraser","year":"2009","unstructured":"Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84\u20138.","journal-title":"CNS Neurosci Ther"},{"issue":"14","key":"451_CR38","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1017\/S0033291717003877","volume":"48","author":"TP Freeman","year":"2018","unstructured":"Freeman TP, Van Der Pol P, Kuijpers W, Wisselink J, Das RK, Rigter S, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med. 2018;48(14):2346\u201352.","journal-title":"Psychol Med"},{"issue":"1","key":"451_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/02791072.2013.873843","volume":"46","author":"GR Greer","year":"2014","unstructured":"Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46(1):73\u20137.","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"451_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2013.805976","volume":"45","author":"A Hazekamp","year":"2013","unstructured":"Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of Cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45(3):199\u2013210.","journal-title":"J Psychoactive Drugs"},{"issue":"951889","key":"451_CR41","first-page":"1","volume":"9","author":"V Hermush","year":"2022","unstructured":"Hermush V, Ore L, Stern N, Mizrahi N, Lederman VE, Schleider LB. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial. Front Med. 2022;9(951889):1\u201315.","journal-title":"Front Med"},{"key":"451_CR42","doi-asserted-by":"publisher","first-page":"106963","DOI":"10.1016\/j.addbeh.2021.106963","volume":"120","author":"ML Hill","year":"2021","unstructured":"Hill ML, Loflin M, Nichter B, Norman SB, Pietrzak RH. Prevalence of cannabis use, disorder, and medical card possession in U.S. military veterans: results from the 2019\u20132020 National Health and Resilience in Veterans Study. Addict Behav. 2021;120:106963.","journal-title":"Addict Behav"},{"issue":"1","key":"451_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/15504263.2019.1652380","volume":"16","author":"C Hindocha","year":"2020","unstructured":"Hindocha C, Cousijn J, Rall M, Bloomfield MAP. The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): a systematic review. J Dual Diagn. 2020;16(1):120\u201339. https:\/\/doi.org\/10.1080\/15504263.2019.1652380.","journal-title":"J Dual Diagn"},{"key":"451_CR44","first-page":"93","volume":"206","author":"M Hoskins","year":"2015","unstructured":"Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Bjpsych. 2015;206:93\u2013100.","journal-title":"Bjpsych"},{"key":"451_CR45","doi-asserted-by":"crossref","unstructured":"Jadad AR, Andrew Moore R, Carroll D, Jenkinson C, John Reynolds DM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17. Available from: http:\/\/www.prosit.de\/images\/3\/36\/Assessing_the_Quality_of_Reports_of_Randomized_Clinical_Trials_Is_Blinding_Necessary.pdf. Cited 2019 Aug 1.","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"451_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","volume":"51","author":"R Jetly","year":"2015","unstructured":"Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585\u20138.","journal-title":"Psychoneuroendocrinology"},{"key":"451_CR47","unstructured":"Kansagara D, O\u2019Neil M, Nugent S, Freeman M, Low A, Kondo K, et al. Evidence-based synthesis program benefits and harms of cannabis in chronic pain or post-traumatic stress disorder: a systematic review. VA ESP Project #05\u2013225. 2017."},{"issue":"91","key":"451_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11916-019-0828-3","volume":"23","author":"S Kind","year":"2019","unstructured":"Kind S, Otis JD, Otis JD. The interaction between chronic pain and PTSD. Curr Pain Headache Rep. 2019;23(91):1\u20137.","journal-title":"Curr Pain Headache Rep"},{"key":"451_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jad.2020.05.132","volume":"274","author":"EM Lafrance","year":"2020","unstructured":"Lafrance EM, Glodosky NC, Bonn-miller M, Cuttler C. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298\u2013304. https:\/\/doi.org\/10.1016\/j.jad.2020.05.132.","journal-title":"J Affect Disord"},{"issue":"1","key":"451_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jts.23013","volume":"37","author":"AJ Lang","year":"2024","unstructured":"Lang AJ, Hamblen JL, Holtzheimer P, Kelly U, Norman SB, Riggs D, et al. A clinician\u2019s guide to the 2023 VA\/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. J Trauma Stress. 2024;37(1):19\u201334.","journal-title":"J Trauma Stress"},{"issue":"8","key":"451_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2023.28934","volume":"6","author":"GT Lapham","year":"2023","unstructured":"Lapham GT, Matson TE, Bobb JF, Luce C, Oliver MM, Hamilton LK, et al. Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use Is Legal. JAMA Netw Open. 2023;6(8):1\u201310.","journal-title":"JAMA Netw Open"},{"key":"451_CR52","doi-asserted-by":"crossref","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Meta-analysis. 2017;5(4):80-4. Available from: https:\/\/www.wjgnet.com\/2308-3840\/full\/v5\/i4\/80.htm. Cited 2025 Dec 24.","DOI":"10.13105\/wjma.v5.i4.80"},{"issue":"e62","key":"451_CR53","first-page":"1","volume":"10","author":"MT Lynskey","year":"2024","unstructured":"Lynskey MT, Athanasiou-fragkouli A, Thurgur H, Schlag AK, Nutt DJ. Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: Real-world evidence. Bjpsych Open. 2024;10(e62):1\u20137.","journal-title":"Bjpsych Open"},{"issue":"32","key":"451_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-020-00038-w","volume":"2","author":"VK Mahabir","year":"2020","unstructured":"Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2020;2(32):1\u201313.","journal-title":"J Cannabis Res"},{"issue":"2","key":"451_CR55","first-page":"3","volume":"6","author":"C Meakin","year":"2020","unstructured":"Meakin C, Fraser G, Boisvert D, Miller C. Use of a synthetic cannabinoid (nabilone) in the ongoing management of posttraumatic stress disorder nightmares in the Canadian Armed Forces: results of an anonymous online survey. J Mil Vet Fam Health. 2020;6(2):3\u20138.","journal-title":"J Mil Vet Fam Health"},{"issue":"5","key":"451_CR56","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","volume":"55","author":"Z Mehmedic","year":"2010","unstructured":"Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. Potency trends of \u03949\u2010THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209\u201317.","journal-title":"J Forensic Sci"},{"issue":"1014630","key":"451_CR57","first-page":"1","volume":"13","author":"N Nacasch","year":"2023","unstructured":"Nacasch N, Avni C, Toren P. Medical cannabis for treatment-resistant combat PTSD. Front Psychiatry. 2023;13(1014630):1\u20137.","journal-title":"Front Psychiatry"},{"key":"451_CR58","doi-asserted-by":"publisher","unstructured":"O'Neil MEO, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder. Ann Intern Med. 2017;167(5):332\u201340. https:\/\/doi.org\/10.7326\/M17-0477.","DOI":"10.7326\/M17-0477"},{"issue":"9","key":"451_CR59","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mp.2013.61","volume":"18","author":"A Neumeister","year":"2013","unstructured":"Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB 1 receptor availability in Post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034\u201340.","journal-title":"Mol Psychiatry"},{"key":"451_CR60","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/dta.1377","volume":"4","author":"T Passie","year":"2012","unstructured":"Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post\u2010traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4:649\u201359.","journal-title":"Drug Test Anal"},{"issue":"11\u201312","key":"451_CR61","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14737175.2022.2155139","volume":"22","author":"M Pillai","year":"2022","unstructured":"Pillai M, Erridge S, Bapir L, Nicholas M, Holvey C, Coomber R, et al. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. Expert Rev Neurother. 2022;22(11\u201312):1009\u201318. https:\/\/doi.org\/10.1080\/14737175.2022.2155139.","journal-title":"Expert Rev Neurother"},{"key":"451_CR62","doi-asserted-by":"publisher","unstructured":"Raz N, Eyal AM, Zeitouni DB, Hen-shoval D, Davidson EM, Danieli A, et al. Selected Cannabis Terpens Synergize with THC to Produce Increased CB1 Receptor Activision. Biochem Pharmacol. 2023;212(115548):1-46. Available from: https:\/\/doi.org\/10.1016\/j.bcp.2023.115548.","DOI":"10.1016\/j.bcp.2023.115548"},{"issue":"3","key":"451_CR63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3934\/Neuroscience.2021022","volume":"8","author":"Y Rehman","year":"2021","unstructured":"Rehman Y, Saini A, Huang S, Sood E, Gill R, Yanikomeroglu S. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. 2021;8(3):414\u201334.","journal-title":"AIMS Neurosci"},{"issue":"1","key":"451_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.23r14862","volume":"85","author":"JD Rodas","year":"2024","unstructured":"Rodas JD, George TP, Hassan AN. A systematic review of the clinical effects of cannabis and cannabinoids in Posttraumatic Stress Disorder symptoms and symptom clusters. J Clin Psychiatry. 2024;85(1):1\u201314.","journal-title":"J Clin Psychiatry"},{"key":"451_CR65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","volume":"34","author":"P Roitman","year":"2014","unstructured":"Roitman P, Mechoulam R, Shalev RCA. Preliminary, open-label, pilot study of add-on oral \u03949-Tetrahydrocannabinol in chronic Post-Traumatic Stress Disorder. Clin Drug Investig. 2014;34:587\u201391.","journal-title":"Clin Drug Investig"},{"key":"451_CR66","doi-asserted-by":"crossref","unstructured":"Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-65. Available from: http:\/\/www.liebertpub.com\/doi\/10.1089\/can.2016.0009. Cited 2019 Dec 17.","DOI":"10.1089\/can.2016.0009"},{"issue":"5","key":"451_CR67","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00213-021-05855-2","volume":"239","author":"C Sakal","year":"2021","unstructured":"Sakal C, Lynskey M, Schlag AK, Nutt DJ. Developing a real world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. Psychopharmacology. 2021;239(5):1147\u201355. https:\/\/doi.org\/10.1007\/s00213-021-05855-2.","journal-title":"Psychopharmacology"},{"key":"451_CR68","doi-asserted-by":"crossref","unstructured":"Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology. 2007;32(6):1384-90. Available from: http:\/\/www.acnp.org\/. Cited 2019 Dec 5.","DOI":"10.1038\/sj.npp.1301246"},{"key":"451_CR69","doi-asserted-by":"crossref","unstructured":"Shapira A, Berman P, Futoran K, Guberman O, Meiri D. Tandem mass spectrometric quantification of 93 terpenoids in Cannabis using static headspace (SHS) injections. Anal Chem. 2019;91(17):1\u20139. Available from: https:\/\/pubs-acs-org.ezlibrary.technion.ac.il\/doi\/pdf\/10.1021\/acs.analchem.9b02844?rand=1gmatc96. Cited 2019 Aug 7.","DOI":"10.1021\/acs.analchem.9b02844"},{"issue":"6","key":"451_CR70","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0272-7358(00)00071-4","volume":"21","author":"TJ Sharp","year":"2001","unstructured":"Sharp TJ, Harvey AG. Chronic pain and posttraumatic stress disorder: Mutual maintenance? Clin Psychol Rev. 2001;21(6):857\u201377.","journal-title":"Clin Psychol Rev"},{"issue":"4","key":"451_CR71","first-page":"397","volume":"10","author":"PA Smith","year":"2017","unstructured":"Smith PA, Chan S, Blake A, Wolt A, Zhang L, Wan BA, et al. Medical cannabis use in military and police veterans diagnosed with post-traumatic stress disorder (PTSD). J Pain Manag. 2017;10(4):397\u2013405.","journal-title":"J Pain Manag"},{"issue":"4","key":"451_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/87551225231180796","volume":"39","author":"SK Stack","year":"2023","unstructured":"Stack SK, Wheate NJ, Moloney NC, Abelev SV, Barlow JW, Schubert EA. The effectiveness and adverse events of Cannabidiol and Tetrahydrocannabinol used in the treatment of anxiety disorders in a PTSD subpopulation: an interim analysis of an observational study. J Pharm Technol. 2023;39(4):172\u201382.","journal-title":"J Pharm Technol"},{"issue":"4","key":"451_CR73","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/appi.ps.202000189","volume":"72","author":"CN Stanciu","year":"2021","unstructured":"Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv. 2021;72(4):429\u201336.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"451_CR74","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/da.22596","volume":"34","author":"MM Steenkamp","year":"2017","unstructured":"Steenkamp MM, Blessing EM, Galatzer\u2010Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207\u201316.","journal-title":"Depress Anxiety"},{"issue":"7","key":"451_CR75","first-page":"30","volume":"323","author":"MM Steenkamp","year":"2020","unstructured":"Steenkamp MM, Litz BT, Marmar CR. First-line psychotherapies for military-related PTSD. JAMA Insights. 2020;323(7):30\u20131.","journal-title":"JAMA Insights"},{"key":"451_CR76","doi-asserted-by":"crossref","unstructured":"Sultan W, Madiedo A, Moreno-Sanz G. Controlled inhalation of THC-predominant cannabis flos mitigates severity of PTSD symptoms and improves quality of sleep and general mood in cannabis-experienced UK civilians: a real-world, observational study. Med Cannabis Cannabinoids. 2024;1\u201319.","DOI":"10.1159\/000540978"},{"key":"451_CR77","doi-asserted-by":"crossref","unstructured":"Sznitman SR, Meiri D, Amit BH, Rosenberg D, Greene T. Posttraumatic stress disorder, sleep and medical cannabis treatment: a daily diary study. J Anxiety Disord. 2022;92:1-7. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887618522001050. Cited 2022 Oct 1.","DOI":"10.1016\/j.janxdis.2022.102632"},{"issue":"7","key":"451_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, Brien KKO, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"1","key":"451_CR79","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000534710","volume":"6","author":"K Vaddiparti","year":"2023","unstructured":"Vaddiparti K, Liu Y, Bottari S, Boullosa CC, Zhou Z, Wang Y, et al. Improved Post-Traumatic Stress Disorder symptoms and related sleep disturbances after initiation of medical marijuana use: evidence from a prospective single arm pilot study. Med Cannabis Cannabinoids. 2023;6(1):160\u20139.","journal-title":"Med Cannabis Cannabinoids"},{"issue":"2","key":"451_CR80","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/09540261.2014.901300","volume":"26","author":"R Vandrey","year":"2014","unstructured":"Vandrey R, Babson KA, Herrmann ES, Bonn-Miller MO. Interactions between disordered sleep, Post-traumatic stress disorder, and substance use disorders. Int Rev Psychiatry. 2014;26(2):237\u201347.","journal-title":"Int Rev Psychiatry"},{"issue":"6","key":"451_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/07067437241303031","volume":"70","author":"SN Vigod","year":"2025","unstructured":"Vigod SN, Frey BN, Clark CT, Grigoriadis S, Barker LC, Brown HK, et al. Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders. Can J Psychiatry. 2025;70(6):429\u201389.","journal-title":"Can J Psychiatry"},{"issue":"578","key":"451_CR82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13063-023-07543-2","volume":"24","author":"Z Walsh","year":"2023","unstructured":"Walsh Z, Mitchell I, Crosby K, Pierre MS, Declerck D, Ong K, et al. A small clinical trial of vaporized cannabis for PTSD: suggestive results and directions for future study. Trials. 2023;24(578):23\u20136. https:\/\/doi.org\/10.1186\/s13063-023-07543-2.","journal-title":"Trials"},{"key":"451_CR83","unstructured":"WHO. The health and social effects of nonmedical cannabis use. 2016."},{"issue":"9","key":"451_CR84","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.4088\/JCP.14m09475","volume":"76","author":"ST Wilkinson","year":"2015","unstructured":"Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174\u201380.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"451_CR85","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4088\/JCP.15r10036","volume":"77","author":"ST Wilkinson","year":"2016","unstructured":"Wilkinson ST, Radhakrishnan R, D\u2019Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016;77(8):1050\u201364.","journal-title":"J Clin Psychiatry"},{"key":"451_CR86","doi-asserted-by":"publisher","unstructured":"Wilson J, Langcake A, Bryant Z, Freeman TP, Leung J, Chan GC, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026;13(1):304-15. https:\/\/doi.org\/10.1016\/S2215-0366(26)00015-5.","DOI":"10.1016\/S2215-0366(26)00015-5"},{"key":"451_CR87","doi-asserted-by":"publisher","first-page":"107758","DOI":"10.1016\/j.nlm.2023.107758","volume":"201","author":"NL Zabik","year":"2023","unstructured":"Zabik NL, Rabinak CA, Peters CA, Iadipaolo A. Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder. Neurobiol Learn Mem. 2023;201:107758.","journal-title":"Neurobiol Learn Mem"},{"key":"451_CR88","doi-asserted-by":"crossref","unstructured":"Zabik NL, Iadipaolo A, Peters CA, Baglot SL, Hill MN, Rabinak CA. Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study. Psychopharmacology. 2024;243(2);235\u201350.","DOI":"10.1007\/s00213-024-06702-w"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-026-00451-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:23:19Z","timestamp":1785460999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-026-00451-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1186\/s42238-026-00451-7","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study involved secondary analysis of publicly available, de-identified data published by previous studies. No human participants, human tissue, or personal identifying information were involved.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RB is affiliated with Syqe Medical Ltd., a company involved in the development of MC delivery systems, JA is a past employee of the company. EF and SG declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}